ROSE12

ROSE12 is a novel monoclonal antibody developed by Chugai Pharmaceutical for the treatment of solid tumors. It is an FcγR affinity-enhanced anti-CTLA-4 switch antibody that selectively binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) in an ATP-dependent manner. This design enhances its ability to deplete intratumoral regulatory T cells (Tregs) via increased affinity for Fcγ receptors (FcγRIIa and FcγRIIIa), resulting in potent anti-tumor efficacy while minimizing systemic immune activation. Preclinical studies have shown that ROSE12 outperforms non-fucosylated ipilimumab in terms of ADCC activity and tumor selectivity, with a favorable safety profile observed in animal models. The drug is currently undergoing phase 1 clinical trials as both monotherapy and combination therapy for patients with locally advanced or metastatic solid tumors[2][3][4][5][7].

Other names

antibody ROSE12